Effectiveness and tolerance of multicorrective topical treatment for infraorbital dark circles and puffiness

Abstract

AbstractBackgroundTreatment of infraorbital dark circles and under‐eye puffiness is challenging due to its multifactorial nature and lack of broadly applicable, effective treatments. A daily skincare treatment option that is multimodal, effective, and tolerable across a broad patient population is an unmet need.AimA multicorrective topical eye cream (MTEC) formulated with Tetrahexyldecyl (THD) ascorbate (vitamin C), prebiotic Inula Helenium, bioavailable peptides, botanical extracts, chrysin, and caffeine is hypothesized to improve the appearance of infraorbital dark circles and under‐eye puffiness by targeting microvasculature congestion and permeability, melanin accumulation and hemoglobin degradation‐related pigmentation, and skin health.MethodsAn IRB approved, open‐label, 12‐week clinical study set out to evaluate the efficacy and tolerability of the MTEC across a broad patient population including varying ethnicities and Fitzpatrick Skin Types (FST). Female subjects (n = 40) ages 35–60 years old, with moderate‐to‐severe under‐eye dark circles, moderate under‐eye puffiness, and mild‐to‐moderate fine lines were enrolled into the study. Objective (Chromameter, VISIA® imaging, and Laser Doppler) and subjective assessments (clinical grading and self‐assessment questionnaire) were conducted at baseline and post‐baseline timepoints.ResultsThirty‐seven subjects completed the study, and the MTEC efficaciously demonstrated short‐term and long‐term improvements in objective and subjective assessments across a broad patient population. Specifically, the MTEC demonstrated significant improvement of infraorbital dark circles, mainly by the reduction in microvasculature congestion and permeability, melanin, and hemoglobin degradation‐related pigmentation.ConclusionTopical application of the MTEC may offer an effective and tolerable treatment option for infraorbital dark circles and puffiness.